Comparable composite endpoints after HLA-matched and HLA-haploidentical transplantation with post-transplantation cyclophosphamide

Shannon R. McCurdy, Yvette L. Kasamon, Christopher G. Kanakry, F Javier Bolanos Meade, Hua Ling Tsai, Margaret Showel, Jennifer A. Kanakry, Heather Symons, Ivana Gojo, B Douglas Smith, Maria Bettinotti, William H. Matsui, Amy Dezern, Carol Ann Huff, Ivan M Borrello, Keith Pratz, Douglas Gladstone, Lode Swinnen, Robert A Brodsky, Mark J LevisRichard F Ambinder, Ephraim J Fuchs, Gary Rosner, Richard J Jones, Leo Luznik

Research output: Contribution to journalArticle


Composite endpoints that not only encompass mortality and relapse, but other critical post-transplant events such as graft-versus- host disease, are being increasingly utilized to quantify survival without significant morbidity after allogeneic blood or marrow transplantation. High-dose, post-transplantation cyclophosphamide reduces severe graft-versus-host disease with allogeneic marrow transplantation, making composite endpoints after this management particularly interesting. We retrospectively analyzed 684 adults with hematologic malignancies who received T-cell-replete bone marrow grafts and cyclophosphamide after myeloablative HLA-matched related (n=192) or unrelated (n=120), or non-myeloablative HLA-haploidentical (n=372) donor transplantation. The median follow up was 4 (range, 0.02-11.4) years. Graft-versus-host disease-free, relapse-free survival was defined as the time after transplantation without grade III-IV acute graft-versus-host disease, chronic graft-versus-host disease requiring systemic treatment, relapse, or death. Chronic graft-versus-host disease-free, relapse-free survival was defined as the time after transplantation without moderate or severe chronic graft-versus-host disease, relapse, or death. One-year graftversus- host disease-free, relapse-free survival and chronic graft-versushost disease-free, relapse-free survival estimates were, respectively, 47% (95% CI: 41-55%) and 53% (95% CI: 46-61%) after myeloablative HLAmatched related, 42% (95% CI: 34-52%) and 52% (95% CI: 44-62%) after myeloablative HLA-matched unrelated, and 45% (95% CI: 40- 50%) and 50% (95% CI: 45-55%) after non-myeloablative HLA-haploidentical donor transplantation. In multivariable models, there were no differences in graft-versus-host disease-free, or chronic graft-versus-host disease-free, relapse-free survival after either myeloablative HLAmatched unrelated or non-myeloablative HLA-haploidentical, compared with myeloablative HLA-matched related donor transplantation. Although limited by inclusion of dissimilar cohorts, we found that posttransplantation cyclophosphamide-based platforms yield comparable composite endpoints across conditioning intensity, donor type, and HLA match.

Original languageEnglish (US)
Pages (from-to)391-400
Number of pages10
Issue number2
StatePublished - 2017


ASJC Scopus subject areas

  • Hematology

Cite this